Search | OpenScholar

Search results

818 results found

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.

Publication: Journal Article

Hauser, RA, LM Shulman, JM Trugman, JW Roberts, A Mori, R Ballerini, and NM Sussman. 2008. “Study of Istradefylline in Patients With Parkinson’s Disease on Levodopa With Motor Fluctuations.”. Mov Disord.

Medical treatment of motor and nonmotor features of Parkinson’s disease.

Publication: Journal Article

Zesiewicz, TA, and RA Hauser. 2007. “Medical Treatment of Motor and Nonmotor Features of Parkinson’s Disease.”. Continuum.

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson’s disease.

Publication: Journal Article

Hauser, RA, L Salin, N Juhel, and VL Konyago. 2007. “Randomized Trial of the Triple Monoamine Reuptake Inhibitor NS 2330 (tesofensine) in Early Parkinson’s Disease.”. Movement Disorders.

Initial management of Parkinson’s disease in a Florida community. J Applied Research 2004;4:95-98.

Publication: Journal Article

Zesiewicz, TA, SN Carter, KL Sullivan, JS Staffetti, PB Dunne, and RA Hauser. 2004. “Initial Management of Parkinson’s Disease in a Florida Community. J Applied Research 2004;4:95-98.”. J Applied Research.

Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Movement Disorders 2004;19:1518-1521.

Publication: Journal Article

Zesiewicz, TA, ED Louis, KL Sullivan, M Menkin, PB Dunne, and RA Hauser. 2004. “Substantial Improvement in a Meige’s Syndrome Patient With Levetiracetam Treatment. Movement Disorders 2004;19:1518-1521.”. Movement Disorders.

Essential tremor. Epidemiology, diagnosis, and treatment. Neurologist 2004;10:250-258.

Publication: Journal Article

Sullivan, KL, RA Hauser, and TA Zesiewicz. 2004. “Essential Tremor. Epidemiology, Diagnosis, and Treatment. Neurologist 2004;10:250-258.”. Neurologist.

Double-blinded, placebo-controlled study of entacapone in levodopa-treated patients with Parkinson disease. Archives of neurology, 61(10), 1563.

Publication: Journal Article

Olanow, CW, K Kieburtz, M Stern, R Watts, JW Langston, M Guarnieri, RA Hauser, and J Hubble. 2004. “Double-Blinded, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Parkinson Disease. Archives of Neurology, 61(10), 1563.”. Archives of Neurology.

Autonomic nervous system dysfunction in Parkinson’s disease. Curr Treat Options Neurol 2003; 5:149-160.

Publication: Journal Article

Zesiewicz, TA, MJ Baker, M Wahba, and RA Hauser. 2003. “Autonomic Nervous System Dysfunction in Parkinson’s Disease. Curr Treat Options Neurol 2003; 5:149-160.”. Curr Treat Options Neurol.

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease.

Publication: Journal Article

Kase, H, S Aoyama, M Ichimura, K Ikeda, A Ishii, T Kanda, K Koga, and . 2003. “Progress in Pursuit of Therapeutic A2A Antagonists: the Adenosine A2A Receptor Selective Antagonist KW6002: Research and Development Toward a Novel Nondopaminergic Therapy for Parkinson’s Disease.”. Neurology.

Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.

Publication: Journal Article

Hauser, RA, JP Hubble, and DD Truong. 2003. “Randomized Trial of the Adenosine A2A Receptor Antagonist Istradefylline in Advanced PD. Neurology 2003;61:297-303.”. Neurology.